In Reply In response to the thoughtful comments by Chang and Jean, we acknowledge that there are limitations related to the design of the ACTIV-6 trial, most of which are noted in the primary publication. We appreciate the opportunity to respond further to these points below.
JAMA Internal Medicine published a clinical update in Research Highlights on 01 Mar 2026.
The item focuses on Metformin Therapy for Patients With COVID-19 Without Obesity—Reply.
Review the original article for the full source wording and details.